题名 | Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. |
链接 | http://journals.lww.com/jto/pages/articleviewer.aspx?year=2015&issue=03000&article=00015&type=abstract |
欢迎光临 科研速递论坛 (http://www.expaper.cn/) | Powered by Discuz! X2.5 |